Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Operating Expenses (2016 - 2025)

Fennec Pharmaceuticals filings provide 15 years of Operating Expenses readings, the most recent being $16.3 million for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 84.34% to $16.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $50.9 million, a 13.24% increase, with the full-year FY2025 number at $50.9 million, up 13.24% from a year prior.
  • Operating Expenses hit $16.3 million in Q4 2025 for Fennec Pharmaceuticals, up from $12.7 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $16.3 million in Q4 2025 to a low of -$5.0 million in Q2 2022.
  • Median Operating Expenses over the past 5 years was $8.0 million (2023), compared with a mean of $8.3 million.
  • Biggest five-year swings in Operating Expenses: tumbled 227.78% in 2022 and later soared 259.53% in 2023.
  • Fennec Pharmaceuticals' Operating Expenses stood at $4.2 million in 2021, then surged by 81.74% to $7.6 million in 2022, then skyrocketed by 52.33% to $11.6 million in 2023, then decreased by 23.32% to $8.9 million in 2024, then skyrocketed by 84.34% to $16.3 million in 2025.
  • The last three reported values for Operating Expenses were $16.3 million (Q4 2025), $12.7 million (Q3 2025), and $12.4 million (Q2 2025) per Business Quant data.